High expression levels of HSP90 are associated with non-small cell lung cancer

Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.

Studies indicate that early clinical trials have confirmed the efficacy of heat shock protein 90 (Hsp90) inhibition as a targeted therapy in non-small-cell lung cancer (NSCLC).

Results suggest that heat shock protein 90 (Hsp90) inhibitors may overcome ligand-triggered resistance in microtubule associated protein-like 4 (EML4)--anaplastic lymphoma kinase (ALK) lung cancer cells.

plasma Hsp90alpha protein levels are useful as a diagnostic biomarker in lung cancer and predict the responses of patients with lung cancer to chemotherapy.

We confirm that miR-628-3p promotes apoptosis and inhibits migration in A549 cells by negatively regulating HSP90. Our results may reveal a novel strategy for lung cancer treatment

Hsp90 inhibition causes regression in murine lung adenocarcinomas driven by mutant EGFR (L858R) with or without T790M